Home › Schizophrenia › NCT03995121
SV2 PET Imaging With [11C]APP311
RecruitingObservational studyHealthy volunteers welcome
Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311
Who can join
Ages 18 to 85 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Willing and able to give voluntary written informed consent * Male and Female subjects, age 18 to 65 years, inclusive Exclusion Criteria: * MRI metal exclusions and claustrophobia. * Education completed is less than 12 years
About the study
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
What is being tested
- [11C]APP311 (drug)
Sponsor: Yale University · Participants: 250 · Started: Dec 1, 2017
Contact the study team
- Angerlyk Frytz, MD · Phone: 203-974-7822
Official record on ClinicalTrials.gov — NCT03995121
Locations in the U.S.
| Connecticut | Conneticut Mental Health Center, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.